E

A oncology biotech to pay attention to

A look at an emerging early stage product which is looking intriguing

January 22, 2024
E

Process is power

Dawn of a new IO era at ESMO23?

October 23, 2023
E

Gunning for new targets, new approaches

From CAR-T cells to protein degradation

September 19, 2023
E

Gritting it out

What are Gritstone up to behind the scenes and where are they headed in the near-term?

July 20, 2021
E

ASCO21 Off the Beaten Track Part 2

A look at some hidden gems in the ASCO program and what it all means in terms of the science.

May 27, 2021
E

Une Baguette Magique

What's under the hood with a personalised cancer vaccine? Quite a lot it seems!

February 12, 2021
E

On finding new targets and boosting existing therapies

Science drives oncology new product development and the AACR special conferences are always a good place…

October 22, 2020
E

New ways of thinking about the immune landscape

How early evolutionary changes in cancer can impact hot/cold regions and patient outcomes

October 13, 2020
E

One swallow does not a summer make

Why you should be wary of the hype surrounding the Iovance TIL data in NSCLC at AACR20

April 27, 2020
E

When everyone zigs, zag

Can we learn from what a patient's tumour is telling us in terms of what the immune system is responding to in order to target it therapeutically?

March 10, 2020
E

Quest for the Holy Grail of Cell Therapy

CAR T cell therapy for solid tumors is the cancer new product development equivalent of the quest for the "Holy Grail."

February 11, 2020
E

Highlights from small biotechs at SITC 2019

Highlights from SITC 2019 including small cap biotechs with novel or innovative approaches to consider

November 12, 2019
E
Cambridge from Bay Bay Boston

An in-depth look at Neon’s updated neoantigen vaccine data

Insights on the updated phase 1b clinical data evaluating Neon's personalized vaccine NEO-PV-01 in combination with nivolumab in advanced cancers?

July 17, 2019
E

mRNA – the language of life

Can mRNA disrupt cancer therapy and boost responses beyond what we see with checkpoint therapy?

July 3, 2019
E

Chipping away at cancer

Gritstone have evolved from start-up biotech to clinical stage oncology company. We catch up with them and discuss their latest progress.

April 25, 2019
E

What did we learn from Neon at ESMO18?

Initial results from the neon NEO-PV-01 phase 1B trial presented by Dr Patrick Ott

October 30, 2018
E

New developments in neoantigen vaccines

A look a progress on NeoVax in GBM, RNA vaccines and even a novel CAR T cell therapy with a difference.

October 8, 2018
E

Iraj Ali leads the way at Achilles Therapeutics

Achilles Therapeutics is an emerging biotech in the cell therapy space that is based on truncal neoantigens

October 31, 2018
E

How Charles Swanton plans to revolutionize treatment of Lung and Renal cancers

What can we learn from the TRACERx studies in lung and renal cancers? Quite a lot, it seems...

April 26, 2018
E

The Future of Cancer Vaccines Part 5 – An Interview with Prof George Coukos

A look at the latest developments in cancer immunotherapy in ovarian cancer, with a particular focus on neoepitopes and cancer vaccines.

October 3, 2017
E

The Future of Cancer Vaccines Part 4 – An Interview with Prof Kees Melief

Interview with Prof Kees Melief, CSO ISA Immune System Activation Pharmaceuticals

October 2, 2017
E

The Future of Cancer Vaccines Part 3 – Interview with Prof Ugur Sahin

A look at Ugur Sahin's BioNTech and personalized mRNA vaccines

September 28, 2017
E

The Future of Cancer Vaccines Part 2 – interview with Dr Ira Mellman

Genentech have several cancer vaccine collaborations in place, where do they see the future going in this niche?

September 27, 2017
E

The Future of Cancer Vaccines – An Interview with Dr Cathy Wu

Part 1 of a new mini-series on cancer vaccines. This one covers an update on Neon's neoantigen approach...

September 26, 2017
E

On Gritstone and neoantigens

A look at a promising biotech in the neoantigen space - what's their approach and how might it fare?

May 4, 2017
E
View of Cambridge and Charles River

Does Neon Therapeutics lead the Neoantigen field?

Update on Neon Tx as they move into commercial new product development with their neoantigen platform.

January 13, 2017
E
Professor Ton Schumacher at CIML40

Is Targeting Neoantigens the Next Frontier in Cancer Immunotherapy?

Interview with Prof Ton Schumacher at scientific meeting to celebrate 40 years of Centre d’Immunologie de Marseille-Luminy (CIML).

September 22, 2016
E

NEON shines the light on Neoantigen targeted Cancer Immunotherapy

Cary Pfeffer of Third Rock Ventures describes how a novel neoantigen vaccine in academia transitioned into a commercial company with exciting prospects...

August 11, 2016
E

Can neoantigen vaccines make a difference in cancer research?

This is the second in our mini-series on neoantigens and looks at whether neoantigen based cancer vaccines can make a difference in the treatment of solid tumors.

August 10, 2016
E

What are neoantigens and why do they matter in cancer immunotherapy?

A primer on neoantigens and their importance in cancer research

August 9, 2016
E

George Coukos Drives Novel Ovarian Cancer Immunotherapies Forward

How can we improve T cell trafficking in ovarian cancer? Professor Coukos highlights numerous ways this could be achieved!

May 16, 2016
E

Adoptive Cell Therapy: An Interview with Dr Steven Rosenberg

We know that TILs can be effective in advanced melanoma, but what about common epithelial solid tumours? Can it work in these cancers too? Find out from Dr Rosenberg's latest work what's happening...

August 12, 2015